Evaluation of paliperidone on social function in patients with chronic schizophrenia  

作　　者：Yan Gu Hong Peng Jingjing Dai Hui Gao Xianghong Yang Jialing Sheng Chen Zhang 

机构地区：[1]Department of Psychiatry, Shanghai Civil Affairs First Mental Health Center [2]Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine

出　　处：《General Psychiatry》2018年第5期63-67,共5页综合精神医学（英文）

基　　金：supported in part by the National Science Fund of China(81771450,81471358);Shanghai Health Bureau scientific research grant(201540029);Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant(20152530)

摘　　要：Background The impairment of social function is widespread in the patients with chronic schizophrenia, which seriously affects family, life and work conditions.Aims The main purpose of this study was to investigate the efficacy of paliperidone in the treatment of social function in chronic schizophrenia.Methods A total of 81 patients who met the standard criteria for schizophrenia and long-term hospitalised inpatients were randomly divided into the treatment group and normal control group following a 1-year prospective follow-up study. The reatment group(41 cases) used paliperidone extended-release tablets for reducing dosage, as appropriate, based on the original treatment strategy; and the control group(40 cases) used the former drugs. All patients were assessed using the Positive and Negative Symptom Scales(PANSS), and the Treatment Emergent Symptom Scale(TESS) was used to assess adverse drug reactions. The Hospitalised Psychiatric Patients' Social Functions Rating Scale(SSPI) was used to assess social function of participants before and after 8 weeks, 6 months and 1 year of treatment.Results At baseline there were no significant differences between the two groups in age, duration of illness, educational background and dosage of antipsychotic drugs(converted into chlorpromazine equivalency). There was statistically significant difference in PANSS positive symptoms by interaction effect(Fgroup×time=18.24, df=3237, p<0.001) and time effect(Ftime=21.66, df=3, p<0.01) and the difference in PANSS positive symptoms by grouping effect(Fgroup=0.68, df=1, p=0.41) was not statistically significant. The difference of grouping effect of PANSS negative symptoms(Fgroup=9.93, df=1, p=0.002), time effect(Ftime=279.15, df=3, p<0.001) and interaction effect(Fgroup×time=279.15, df=3237, p<0.001) were statistically significant. There were statistically significant differences in the grouping effect(Fgroup=6.59, df=1, p=0.012), time effect(Ftime=152.97, df=3, p<0.001) and interaction effect(Fgroup×time=148.82, df=3237, p<0.001)Background The impairment of social function is widespread in the patients with chronic schizophrenia, which seriously affects family, life and work conditions.Aims The main purpose of this study was to investigate the efficacy of paliperidone in the treatment of social function in chronic schizophrenia.Methods A total of 81 patients who met the standard criteria for schizophrenia and long-term hospitalised inpatients were randomly divided into the treatment group and normal control group following a 1-year prospective follow-up study. The reatment group(41 cases) used paliperidone extended-release tablets for reducing dosage, as appropriate, based on the original treatment strategy; and the control group(40 cases) used the former drugs. All patients were assessed using the Positive and Negative Symptom Scales(PANSS), and the Treatment Emergent Symptom Scale(TESS) was used to assess adverse drug reactions. The Hospitalised Psychiatric Patients' Social Functions Rating Scale(SSPI) was used to assess social function of participants before and after 8 weeks, 6 months and 1 year of treatment.Results At baseline there were no significant differences between the two groups in age, duration of illness, educational background and dosage of antipsychotic drugs(converted into chlorpromazine equivalency). There was statistically significant difference in PANSS positive symptoms by interaction effect(Fgroup×time=18.24, df=3237, p<0.001) and time effect(Ftime=21.66, df=3, p<0.01) and the difference in PANSS positive symptoms by grouping effect(Fgroup=0.68, df=1, p=0.41) was not statistically significant. The difference of grouping effect of PANSS negative symptoms(Fgroup=9.93, df=1, p=0.002), time effect(Ftime=279.15, df=3, p<0.001) and interaction effect(Fgroup×time=279.15, df=3237, p<0.001) were statistically significant. There were statistically significant differences in the grouping effect(Fgroup=6.59, df=1, p=0.012), time effect(Ftime=152.97, df=3, p<0.001) and interaction effect(Fgroup×time=148.82, df=3237, p<0.001)

关 键 词：PROSPECTIVE FOLLOW-UP Positive and NEGATIVE SYMPTOM Scales(PANSS) 

分 类 号：R74[医药卫生—神经病学与精神病学]